---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-25-004115"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:39:22.578706+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Prelude gets $60M from Incyte for JAK2V617F option; pauses SMARCA2; CMO resigns

## Summary
- Incyte receives exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program for $100M exercise price, plus up to $775M milestones and single-digit royalties.
- Prelude receives $60M in capital: $35M upfront plus $25M equity investment (6.25M shares at $4.00 each).
- Company pauses clinical development of SMARCA2 degrader program to prioritize JAK2V617F and KAT6A degrader programs.
- President and CMO Jane Huang resigns; board member Dr. Victor Sandor steps in to oversee clinical development.
- Cash runway extended into 2027 (potentially 2028 if Incyte exercises option); preliminary cash ~$52M as of Oct 31, 2025.

## SEC filing metadata
- accession: 0000929638-25-004115
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000092963825004115/0000929638-25-004115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000092963825004115/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-25-004115
- JSON: https://secwatch.observer/filing/0000929638-25-004115.json
- Plain text: https://secwatch.observer/filing/0000929638-25-004115.txt

## Key facts
- Equity Issuances
  Prelude Therapeutics Inc issued 6,250,000 shares of common stock to Incyte Corporation for $4.00 per share for a total of $25 million.
  - Security: common stock
  - Shares: 6,250,000 shares
  - Purchaser: Incyte Corporation
  - Consideration: $4.00 per share for a total of $25 million
  source text: the Company entered into a securities purchase agreement with Incyte (the "Securities Purchase Agreement"), pursuant to which Incyte has agreed to purchase 6,250,000 shares (the "Shares") of the Company’s non-voting common stock (the "Non-Voting Common Stock") at a price of $4.00 per share for a total of $25 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000092963825004115/0000929638-25-004115-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.